GlassScriptPhysician profile
Mary Conti
NPI 1518501220
$7,161.48
in general payments reported to CMS, 2019-2025
35 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,219 · 2022: $1,348 · 2023: $1,358 · 2024: $1,818 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,593.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,374.81 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.58 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $638.41 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $585.75 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $563.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $498.90 | 2021-2024 | Xarelto |
| Amgen INC. | $438.74 | 2023-2025 | Repatha, Repatha |
| Heartflow, INC. | $235.99 | 2024-2025 | |
| Pfizer INC. | $220.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $210.70 | 2022-2025 | Verquvo |
| Genzyme Corporation | $188.99 | 2022-2024 | |
| Edwards Lifesciences Corporation | $182.36 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $158.52 | 2022-2025 | |
| Biosense Webster, INC. | $129.29 | 2023-2024 | Octaray Mapping Catheter, Qdot Micro Catheter |
| Lexicon Pharmaceuticals, INC. | $126.10 | 2023-2024 | Inpefa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.48 | 2021-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $114.87 | 2021 | |
| Daiichi Sankyo INC. | $102.59 | 2021-2023 | Injectafer |
| Baxter Healthcare | $77.88 | 2023 | Preveleak |
| Lantheus Medical Imaging, INC. | $75.10 | 2024-2025 | |
| Abiomed | $40.83 | 2025 | |
| Kestra Medical Technology Services, INC. | $35.49 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $34.98 | 2024 | Arcalyst |
| Medtronic, INC. | $34.64 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.95 | 2025 | Amvuttra |
| Corcym INC | $33.08 | 2023 | Miami Instruments |
| Octapharma USA, INC. | $28.44 | 2025 | Fibryga |
| Boston Scientific Corporation | $23.77 | 2022 | |
| Inspire Medical Systems, INC. | $21.68 | 2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $19.54 | 2023 | Arcalyst |
| Angiodynamics, INC. | $16.45 | 2022 | |
| Amryt Pharma Holdings LTD | $15.20 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.89 | 2025 | Evkeeza |
| Esperion Therapeutics, INC. | $13.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.